Sciety

Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.

Encare was established in 2009 to implement the ERAS Protocols on a global basis by - providing training to health care professionals on the ERAS Protocols - providing an interactive and web-based information system for evidence based - best practice management (EBM) The company has developed an interactive, user-friendly interface for the collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence. The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings. Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States. The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery.

Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits. The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity.

Capitainer enables patients to collect their own volume-defined dried blood spot at home. Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitainer offers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.

Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.

Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

Cavis Technologies is an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.

Predicare develops a decision support system for healthcare called RETTS. RETTS' fast emergency triage and treatment system works by measuring and assessing vital parameters at the first examination, as well as by gathering a structured and standardized medical history regarding the reason for the visit and the patient’s current symptoms. Predicare was founded in 2011 and is headquartered in Gothenburg, Sweden.

Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

SINGLE TECHNOLOGIES develops a new type of single-molecule-sensitive 3D sequencing system.They provide single-molecule detection, fiber optics, 3D imaging, genomics, sequencing, and 3-D Seq.

Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit.

Likvor has developed a unique instrument for measuring the cerebrospinal fluid (brain fluid) pressure and flow. Likvor AB is an Umeå based medical device company which has developed a system to be used in neurological investigations. Likvor CELDA System is the result of close to 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Likvor AB is marketing Likvor CELDA System and CELDA Tools. Likvor AB was established in 2007. Likvor AB first product Likvor CELDA System, was available to the market in 2009 when it was CE-marked. The company is certified according to ISO-13485. Likvor AB continues to develop new methods and devices in the area of CSF dynamics, together with the researchers at Umeå University and Umeå University Hospital.

Lipigon Pharmaceuticals is specialized in fat metabolism and develops new blood lipids. Lipigon is currently focusing on developing drugs directed against the enzyme lipoprotein lipase (LPL). People with low activity at LPL have a higher incidence of elevated blood fats and also related disorders such as insulin resistance and metabolic syndrome. Thanks to Lipigon's expertise in this area, AstraZeneca has chosen to enter into a cooperation agreement with the Company to develop LPL-based pharmaceuticals. Lipigon can receive up to $ 110 million in compensation at achieved milestones related to development and sales.

CARTANA is a Swedish Biotechnology company that maps gene expression in brain tissue via In Situ Sequencing (ISS), the 4th generation of sequencing technologies. Their solution enables simultaneous analysis of hundreds of genes within all cells comprising a tissue, without losing tissue morphology, with high sensitivity and throughput in several research areas. - Revolutionary research and biomarker discovery - Treatment validation - Future diagnostic tool

Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.

The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

Medpro Clinic Group is a healthcare business that operates six innovative care centers and provides care with a personal service and high standards. Medpro Clinic's operations are run by a dedicated staff who are passionate about care with high quality and preserved integrity. Medpro Clinic Group is headquartered in Sweden.

Liv Diagnostics develops a unique product for measuring the migration capacity of tumor cells. It provides predictive information about the risk of metastasis. Liv Diagnostics' technology is based on direct analysis of cancer cell behavior, which is a new approach in comparison with indirect diagnostic methods, allowing physicians to mimic the cells' natural environment in the human body to directly observe how the cells behave and treat efficiently. Liv Diagnostics' product, CellRACE, provides quantified information on the risk of metastasis by analyzing the migration behavior of living cells. Liv Diagnostics was founded in 2016 and is headquartered in Mölndal, Sweden.

Swedish Adrenaline was formed in 2013 with the mission to develop new electronic products for the Sport and Health markets. The fact that these markets differ very much resulted in 2015 in the founding of two subsidiaries to Swedish Adrenaline, namely, Raytelligence and Innowearable. Swedish Adrenaline became by doing so a holding company. Innowearable is devoted to Sport Electronics and Raytelligence is focused on microwave sensors for the healthcare- and industrial markets. In 2015 Raytelligence received a grant from the Swedish Innovation Bureau - Vinnova to develop a radar sensor for vital sign monitoring. Raytelligence showed in 2016 the first version of the 60 GHz sensor for vital sign monitoring and also a cloud service was demonstrated. In 2017 the sensor RayVS1 was certified for home use. This year the first industrial client was signed for development and delivery of sensors to the road construction market as well as signing a partnership with a major Swedish IT-provider to the e-Health market. The Raytelligence team is a blend of people with competence ranging from industrial design to radar signal processing.

1928 Diagnostics is a digital health company, crunching DNA data in the cloud, to enable healthcare providers fight antibiotic resistance. Our software service provide revolutionary outbreak tracing and diagnostics for full infection control at any hospital.

MedFilm business idea is to convey information about surgical interventions to patients through animation and film. MedFilm, we help the health-care sector to communicate information about operations and treatments to patients simply and effectively. We provide 3D animated patient films in more than a dozen languages in order to improve patient understanding, confidence, and participation. The films are shown in hospitals around Scandinavia. Our film tablets provide information about each operation when the patient is admitted and when they wake up. The films are also shown on waiting room screens as well as online at patients’ homes.

The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.

The PreciseInhale patented aerosol generation R&D platform delivers respirable dry powder aerosols from preclinical cell studies all the way through to human clinical trials, significantly accelerating drug development timelines. The platform’s one-animal-at-a-time system requires just milligrams, not grams of costly test substance for a full PK study and delivers high-resolution lung data of, typically, <10% SD. We carry out Contract Research for novel and generic inhalation drug developers, toxicology and environmental research institutes and university research institutes in the inhalation and aerosolization field.

Learning To Sleep offers clinically proven sleep improvement programs for people with sleep disorder through web and mobile devices. Their products has already helped over 40 000 people to live a better life and their unique business model establish also a strong relation between patients and their physicist.

Attana’s third generation biosensors are today used to determine specificity, kinetics and affinity -among other binding characteristics- of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria. their technology has been validated by academic institutions, biotech companies and big-pharma across the world.